Bio-Rad Laboratories has signed an agreement to acquire certain diagnostic businesses of Biotest for 45 million euros, the terms of which were not disclosed. The transaction is subject to closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2010.
Biotest develops, manufactures and markets pharmaceutical, biotherapeutic and diagnostic products. Integrating Biotest’s diagnostic business into Bio-Rad’s product portfolio will broaden the company’s offering in the area of immunohematology and provide Bio-Rad access to the US markets with a full range of products.
Phone: 0011 1 510 724 7000
Cayman Chemical Cellular Metabolism Screening Library
Cayman Chemical's Cellular Metabolism Screening Library consists of two plates and contains...
Navinci Diagnostics NaveniFlex Cell Red proximity ligation assay kit
Optimised for cell samples, the kit enables fluorescence visualisation of protein–protein...
Lonza TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium
The products provide researchers and manufacturers with high-performance, scalable and...
